ArticleHealth science reports2026
The Potential Role of MicroRNAs as Cardioprotective Agents During Cardioplegia: A Preliminary Qualitative Systematic Review.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Recent advancements in gene expression studies have shed light on the role of non-coding RNAs in negatively regulating mRNA and inhibiting mRNA translation. Given the significant impact of miRNAs on cardiovascular function, our review aims to comprehensively explore their contribution to mitigating heart injury and their protective effects during cardioplegic-induced cardiac arrest. Methods: A systematic search conducted in December 2023 across PubMed, Web of Science, Scopus, and Google Scholar yielded valuable insights. Results: Our findings indicate that cardioplegia leads to the upregulation of several miRNAs, including miR-208b, miR-499-5p, miR-10b, miR-96, miR-339-5p, and miR-483-3p, alongside the downregulation of miR-139-5p, and miR-194-5p. Many of these miRNAs are implicated in cardiac pathophysiology, particularly in myocardial injury following cardioplegia in on-pump cardiac surgery. Conclusion: While current applications of discovered miRNAs primarily focus on early diagnosis and prognosis of cardiac conditions, their therapeutic potential holds promise for revolutionizing the management of various heart diseases in the future. By elucidating the intricate roles of miRNAs in cardiac health and disease, this review underscores the importance of harnessing their therapeutic potential for improved patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.